One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
Masahiro Natsuaki(Saga University), Takeshi Kimura(Kyoto University), Hisayuki Okada(Seirei Hamamatsu General Hospital), Masaharu Akao(Kyoto Medical Center), Kozo Hoshino(Naga Municipal Hospital), Mitsuru Abe(Kyoto Medical Center), Kei Yunoki(Osaka City General Hospital), Masashi Yamamoto, Yutaka Furukawa(Kobe City Medical Center General Hospital), Erika Yamamoto(Kyoto University), Hiroki Shiomi(Kyoto University), Kazushige Kadota(Kurashiki Central Hospital), Shogo Shimizu, Takeshi Morimoto(Hyogo Medical University), Kōichi Nakao(Saiseikai Kumamoto Hospital), Ken Kozuma(Teikyo University Hospital), Shinji Miki(Hyogo Medical University), Tetsuya Ishikawa(Saitama Prefecture), Kengo Tanabe, Yoshihiro Morino(Iwate Medical University), Keiichi Igarashi(Hokkaido hospital), Kazuya Kawai(Chikamori Hospital)
Cited by 76
Related Papers
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
|Circulation Journal|2020|345